Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Claudin18.2-Targeted Activated DC and CAR-T Therapy in Advanced Pancreatic Cancer
NCT07416240Phase 1Recruiting
- Sponsor
- Hainan Cancer Hospital
- Start
- Feb 2026
- Primary completion
- Feb 2028
- Modality
- Whole Cell Cancer Vaccines, CAR-T Cells, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Claudin18.2 Targeted Activated Dendritic Cells and Claudin18.2 CAR-T cells in pancreatic cancer (PC), sponsored by Hainan Cancer Hospital. Primary endpoint: Adverse Events at 2 years. Started Feb 2026; status: recruiting.
02
Drugs
Claudin18.2 Targeted Activated Dendritic CellsClaudin18.2 CAR-T cells
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT07416240.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07416240.